Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Joy Ho

Showing results (51-60 of 81) with videos related to

Pageof 9
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|January 13, 2026
Cytogenetic Testing in Newly Diagnosed Multiple Myeloma: Real World Evidence on Clinical Features and Adverse Outcomes for High Risk GroupsGhassan Zammar, Bradley Augustson, Elizabeth Moore, et al.
Internal Medicine Journal|March 7, 2023
The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma AustraliaShirlene Sim, Anna Kalff, Gina Tuch, et al.
Leukemia|February 1, 2020
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 studyNizar J Bahlis, Meletios A Dimopoulos, Darrell J White, et al.
Oncoimmunology|April 11, 2018
A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remissionJennifer L Hsu, Christian E Bryant, Michael S Papadimitrious, et al.
Blood Advances|September 28, 2020
Inverse relationship between oligoclonal expanded CD69- TTE and CD69+ TTE cells in bone marrow of multiple myeloma patientsSlavica Vuckovic, Christian E Bryant, Ka Hei Aleks Lau, et al.
The Lancet. Haematology|July 18, 2025
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trialVania Hungria, Marek Hus, ChengCheng Fu, et al.
The Lancet. Haematology|February 13, 2025
Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent β-thalassaemia (BELIEVE): final results from a phase 3 randomised trialMaria Domenica Cappellini, Vip Viprakasit, Pencho Georgiev, et al.
Blood|February 17, 2026
Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphomaMark R Dowling, Edward Robert Scheffer Cliff, Anthony Jeffrey, et al.
The New England Journal of Medicine|December 4, 2018
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell LymphomaStephen J Schuster, Michael R Bishop, Constantine S Tam, et al.
Blood Cancer Journal|November 5, 2020
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUXJonathan L Kaufman, Meletios A Dimopoulos, Darrell White, et al.
Pageof 9

Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
Clinical Lymphoma, Myeloma & Leukemia|January 13, 2026
Cytogenetic Testing in Newly Diagnosed Multiple Myeloma: Real World Evidence on Clinical Features and Adverse Outcomes for High Risk GroupsGhassan Zammar, Bradley Augustson, Elizabeth Moore, et al.
Internal Medicine Journal|March 7, 2023
The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma AustraliaShirlene Sim, Anna Kalff, Gina Tuch, et al.
Leukemia|February 1, 2020
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 studyNizar J Bahlis, Meletios A Dimopoulos, Darrell J White, et al.
Oncoimmunology|April 11, 2018
A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remissionJennifer L Hsu, Christian E Bryant, Michael S Papadimitrious, et al.
Blood Advances|September 28, 2020
Inverse relationship between oligoclonal expanded CD69- TTE and CD69+ TTE cells in bone marrow of multiple myeloma patientsSlavica Vuckovic, Christian E Bryant, Ka Hei Aleks Lau, et al.
The Lancet. Haematology|July 18, 2025
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trialVania Hungria, Marek Hus, ChengCheng Fu, et al.
The Lancet. Haematology|February 13, 2025
Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent β-thalassaemia (BELIEVE): final results from a phase 3 randomised trialMaria Domenica Cappellini, Vip Viprakasit, Pencho Georgiev, et al.
Blood|February 17, 2026
Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphomaMark R Dowling, Edward Robert Scheffer Cliff, Anthony Jeffrey, et al.
The New England Journal of Medicine|December 4, 2018
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell LymphomaStephen J Schuster, Michael R Bishop, Constantine S Tam, et al.
Blood Cancer Journal|November 5, 2020
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUXJonathan L Kaufman, Meletios A Dimopoulos, Darrell White, et al.
Pageof 9